OncoMatch/Clinical Trials/NCT06601283
Vitamin C Plus Cordyceps to Chemotherapy Related Anemia in Pancreatic Cancer
Is NCT06601283 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies Vitmain C plus herbal medicine for pancreatic cancer.
Treatment: Vitmain C plus herbal medicine — The purpose of this study is to evaluate the efficacy of low-dose vitamin C plus herbal medicine on improving the quality of life for metastatic pancreatic cancer patients receiving gemcitabine and nab-paclitaxel chemotherapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: any anti-tumor therapy
Lab requirements
Blood counts
Hemoglobin (Hgb) ≥ 8 g/dL
Kidney function
Renal insufficiency or dialysis [excluded]
Cardiac function
Cardiovascular disease (Class III or IV heart failure as defined by the New York Heart Association classification, congestive heart failure (CHF), myocardial infarction in the past 6 months, unstable arrhythmia or unstable angina, cerebral infarction within 3 months, etc) [excluded]
Adequate organ performance based on laboratory blood tests. Hemoglobin (Hgb) ≥ 8 g/dL. Renal insufficiency or dialysis [excluded]. Cardiovascular disease (Class III or IV heart failure as defined by the New York Heart Association classification, congestive heart failure (CHF), myocardial infarction in the past 6 months, unstable arrhythmia or unstable angina, cerebral infarction within 3 months, etc) [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify